AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05705856 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
Study NCT05902520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP CD8 TIL
Description: intravenous infusion of T cell suspension
Study NCT05902520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP CD8 TIL KD
Description: intravenous infusion of T cell suspension
Study NCT05902520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose IL-2
Description: Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
Study NCT05065983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP, adjuvanted
Description: Adjuvanted formulation includes aluminum hydroxide
Study NCT06301646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06301646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT06301646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06301646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of sputum sample
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of sputum sample
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Brush Biopsy
Description: Undergo bronchial brush biopsy
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchial Brush Biopsy
Description: Undergo bronchial brush biopsy
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy
Study NCT05411107 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Undergo bronchoscopy
Study NCT05411107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Given PO
Study NCT06049615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS® System
Description: The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
Study NCT06273410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
Study NCT06273410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N + Adhesive
Description: Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
Study NCT06273410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk Fill Composite
Description: Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
Study NCT05517356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored management strategies
Description: Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved.
Study NCT06114225 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
Description: participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
Study NCT02487134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIGR Matrix
Description: Reinforcement of the suture line with resorbable mesh
Study NCT02487134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Closure of the abdomen with conventional technique
Study NCT05109702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Tanfanercept Ophthalmic Solution
Description: Tanfanercept ophthalmic solution.
Study NCT05109702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle solution.
Study NCT05109702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo vehicle solution.
Study NCT05411107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05411107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04874584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTNSM
Description: The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
Study NCT04874584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy Education
Description: Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
Study NCT05463159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
Study NCT05463159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
Study NCT04780841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue
Study NCT04780841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment that looks identical to experimental treatment
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine low potency
Description: 1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine medium potency
Description: 1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine high potency
Description: 1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
Study NCT04950140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia
Description: Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
Study NCT04950140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery for the Treatment of Parastomal Hernia
Description: Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
Study NCT06122987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II and hydrocortisone sodium succinate
Description: Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
Study NCT04889963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
Study NCT04889963 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
Study NCT04889963 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
Study NCT05467462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V carbetocin administration
Description: Group I: carbetocin was intravenously administered immediately after birth of the baby.
Study NCT05467462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
Study NCT05467462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V carbetocin and tranexamic acid administration
Description: Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
Study NCT05467462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin and tranexamic acid administration
Description: Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
Study NCT04695548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
Study NCT04695548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
Study NCT04695548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
Study NCT04695548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic passive stretching
Description: The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
Study NCT05411107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine Lot 1
Description: 1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine Lot 2
Description: 1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
Study NCT05394103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q901
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
Study NCT05394103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: KEYTRUDA® (pembrolizumab) will be administered Q6W
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
Study NCT05706649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: 21 day diet that excludes any form of meat and other animal products, including dairy products.
Study NCT05124353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
Study NCT05529251 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Description: Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes > 2 cm
Study NCT05529251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC7
Description: Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh
Study NCT05084508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh